Sudan Loganathan
Stock Analyst at Stephens & Co.
(0.66)
# 3,756
Out of 4,827 analysts
35
Total ratings
25.93%
Success rate
-25.81%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sudan Loganathan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ELEV Elevation Oncology | Downgrades: Equal-Weight | $5 | $0.33 | +1,414.69% | 4 | Mar 24, 2025 | |
| IMNM Immunome | Reiterates: Overweight | $30 | $7.72 | +288.60% | 2 | Mar 20, 2025 | |
| CPRX Catalyst Pharmaceuticals | Reiterates: Overweight | $33 | $22.64 | +45.76% | 2 | Feb 27, 2025 | |
| ADCT ADC Therapeutics | Maintains: Overweight | $6 → $8 | $1.28 | +527.45% | 2 | Feb 24, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Overweight | $50 | $18.27 | +173.67% | 2 | Feb 14, 2025 | |
| EXEL Exelixis | Reiterates: Equal-Weight | $29 | $36.91 | -21.43% | 4 | Feb 12, 2025 | |
| BCYC Bicycle Therapeutics | Reiterates: Equal-Weight | $15 | $8.20 | +82.93% | 2 | Jan 22, 2025 | |
| NRIX Nurix Therapeutics | Reiterates: Overweight | $31 | $9.78 | +216.97% | 3 | Jan 21, 2025 | |
| KYMR Kymera Therapeutics | Reiterates: Overweight | $60 | $31.03 | +93.36% | 2 | Jan 21, 2025 | |
| BPMC Blueprint Medicines | Reiterates: Overweight | $140 | $100.87 | +38.79% | 2 | Jan 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $1.47 | +241.30% | 2 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $4 | $1.59 | +151.57% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $55 | $6.78 | +711.21% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $13 | $1.11 | +1,076.47% | 1 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $14.45 | +73.01% | 2 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $0.37 | +1,251.35% | 2 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.84 | +986.96% | 1 | May 14, 2024 |
Elevation Oncology
Mar 24, 2025
Downgrades: Equal-Weight
Price Target: $5
Current: $0.33
Upside: +1,414.69%
Immunome
Mar 20, 2025
Reiterates: Overweight
Price Target: $30
Current: $7.72
Upside: +288.60%
Catalyst Pharmaceuticals
Feb 27, 2025
Reiterates: Overweight
Price Target: $33
Current: $22.64
Upside: +45.76%
ADC Therapeutics
Feb 24, 2025
Maintains: Overweight
Price Target: $6 → $8
Current: $1.28
Upside: +527.45%
IDEAYA Biosciences
Feb 14, 2025
Reiterates: Overweight
Price Target: $50
Current: $18.27
Upside: +173.67%
Exelixis
Feb 12, 2025
Reiterates: Equal-Weight
Price Target: $29
Current: $36.91
Upside: -21.43%
Bicycle Therapeutics
Jan 22, 2025
Reiterates: Equal-Weight
Price Target: $15
Current: $8.20
Upside: +82.93%
Nurix Therapeutics
Jan 21, 2025
Reiterates: Overweight
Price Target: $31
Current: $9.78
Upside: +216.97%
Kymera Therapeutics
Jan 21, 2025
Reiterates: Overweight
Price Target: $60
Current: $31.03
Upside: +93.36%
Blueprint Medicines
Jan 2, 2025
Reiterates: Overweight
Price Target: $140
Current: $100.87
Upside: +38.79%
Nov 19, 2024
Reiterates: Overweight
Price Target: $5
Current: $1.47
Upside: +241.30%
Nov 18, 2024
Initiates: Equal-Weight
Price Target: $4
Current: $1.59
Upside: +151.57%
Nov 18, 2024
Initiates: Overweight
Price Target: $55
Current: $6.78
Upside: +711.21%
Nov 8, 2024
Initiates: Overweight
Price Target: $13
Current: $1.11
Upside: +1,076.47%
Aug 6, 2024
Reiterates: Overweight
Price Target: $25
Current: $14.45
Upside: +73.01%
May 24, 2024
Reiterates: Overweight
Price Target: $5
Current: $0.37
Upside: +1,251.35%
May 14, 2024
Initiates: Overweight
Price Target: $20
Current: $1.84
Upside: +986.96%